Related Experiment Video
Updated: Aug 21, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Recognizing and managing common toxicities in patients receiving antiretroviral therapy
M Keith Rawlings1, Kimberly Y Smith
1Peabody Health Center, Dallas, Texas, USA.
Abstract:
Each of the 3 traditional classes of antiretroviral drugs (nucleoside/nucleotide reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors [PIs]) has characteristic sets of toxicities that are not found with the other drug classes. On the other hand, lipodystrophy, which was thought to be specific to PIs, is now known to be common to all 3 classes of drugs. An understanding of the drug-specific, class-specific, and general toxicities and side effects of antiretroviral drugs will help the clinician tailor treatment regimens to individual patients.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Therapeutic Drug Monitoring: Affecting Factors
Drug Toxicity: Risk factors
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Overview
Drug Toxicity: Dose-Dependent Reactions

